In this approach, all individuals newly diagnosed with CRC undergo either tumor-based dMMR genetic testing or immunohistochemistry (IHC) testing to check for the absence of DNA mismatch repair (MMR) proteins (MLH1, MSH2, MSH6 or PMS2). The gene discussed is PMS2; the disease is colorectal carcinoma.